Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
Matthew J. Armstrong, Diana Hull, Kathy Guo, et al.
Journal of Hepatology (2015) Vol. 64, Iss. 2, pp. 399-408
Open Access | Times Cited: 378

Showing 1-25 of 378 citing articles:

American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity
W. Timothy Garvey, Jeffrey I. Mechanick, Elise M. Brett, et al.
Endocrine Practice (2016) Vol. 22, pp. 1-203
Open Access | Times Cited: 1404
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Philip N. Newsome, Kristine Buchholtz, Kenneth Cusi, et al.
New England Journal of Medicine (2020) Vol. 384, Iss. 12, pp. 1113-1124
Open Access | Times Cited: 1337
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
Stergios A. Pοlyzos, Јannis Kountouras, Christos S. Mantzoros
Metabolism (2018) Vol. 92, pp. 82-97
Closed Access | Times Cited: 961
Lipotoxicity and the gut-liver axis in NASH pathogenesis
Fabio Marra, Gianluca Svegliati‐Baroni
Journal of Hepatology (2017) Vol. 68, Iss. 2, pp. 280-295
Closed Access | Times Cited: 696
Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases
Varman T. Samuel, Gerald I. Shulman
Cell Metabolism (2017) Vol. 27, Iss. 1, pp. 22-41
Open Access | Times Cited: 610
Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
Juan Pablo Arab, Saul J. Karpen, Paul A. Dawson, et al.
Hepatology (2016) Vol. 65, Iss. 1, pp. 350-362
Open Access | Times Cited: 528
NAFLD as a continuum: from obesity to metabolic syndrome and diabetes
Amélio F. Godoy‐Matos, Wellington S. Silva Júnior, Cynthia Melissa Valério
Diabetology & Metabolic Syndrome (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 483
Non-alcoholic fatty liver disease and diabetes
Jonathan Hazlehurst, Conor Woods, Thomas Marjot, et al.
Metabolism (2016) Vol. 65, Iss. 8, pp. 1096-1108
Open Access | Times Cited: 467
The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis
Chiara Saponaro, Melania Gaggini, Fabrizia Carli, et al.
Nutrients (2015) Vol. 7, Iss. 11, pp. 9453-9474
Open Access | Times Cited: 456
Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease
Reenam S. Khan, Fernando Bril, Kenneth Cusi, et al.
Hepatology (2018) Vol. 70, Iss. 2, pp. 711-724
Open Access | Times Cited: 432
The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD)
Daniela Maria Tănase, Evelina Maria Gosav, Claudia Florida Costea, et al.
Journal of Diabetes Research (2020) Vol. 2020, pp. 1-16
Open Access | Times Cited: 421
Beneficial Effects of Adiponectin on Glucose and Lipid Metabolism and Atherosclerotic Progression: Mechanisms and Perspectives
Hidekatsu Yanai, Hiroshi Yoshida
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 5, pp. 1190-1190
Open Access | Times Cited: 391
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
Yaron Rotman, Arun J. Sanyal
Gut (2016) Vol. 66, Iss. 1, pp. 180-190
Open Access | Times Cited: 384
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Amalia Gastaldelli, Kenneth Cusi
JHEP Reports (2019) Vol. 1, Iss. 4, pp. 312-328
Open Access | Times Cited: 357
The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways
Günaj Rakipovski, Bidda Rolin, Jane Nøhr, et al.
JACC Basic to Translational Science (2018) Vol. 3, Iss. 6, pp. 844-857
Open Access | Times Cited: 345
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Daniel Ferguson, Brian N. Finck
Nature Reviews Endocrinology (2021) Vol. 17, Iss. 8, pp. 484-495
Open Access | Times Cited: 340
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
Amalia Gastaldelli, Kenneth Cusi, Laura Fernández Landó, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 6, pp. 393-406
Closed Access | Times Cited: 321
Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Sumio Watanabe, Etsuko Hashimoto, Kenichi Ikejima, et al.
Journal of Gastroenterology (2015) Vol. 50, Iss. 4, pp. 364-377
Open Access | Times Cited: 307
Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies
Nishanth E. Sunny, Fernando Bril, Kenneth Cusi
Trends in Endocrinology and Metabolism (2016) Vol. 28, Iss. 4, pp. 250-260
Closed Access | Times Cited: 275
Evolution of NAFLD and Its Management
Manpreet S. Mundi, Saketh R. Velapati, Janki Patel, et al.
Nutrition in Clinical Practice (2019) Vol. 35, Iss. 1, pp. 72-84
Open Access | Times Cited: 249
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
Kalliopi Pafili, Michael Roden
Molecular Metabolism (2020) Vol. 50, pp. 101122-101122
Open Access | Times Cited: 240
Treatment options for alcoholic and non-alcoholic fatty liver disease: A review
Sukhpreet Singh, Natalia A. Osna, Kusum K. Kharbanda
World Journal of Gastroenterology (2017) Vol. 23, Iss. 36, pp. 6549-6570
Open Access | Times Cited: 229
Mouse models of nonalcoholic steatohepatitis in preclinical drug development
Henrik H. Hansen, Michael Feigh, Sanne Skovgård Veidal, et al.
Drug Discovery Today (2017) Vol. 22, Iss. 11, pp. 1707-1718
Open Access | Times Cited: 218
Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy
Anne Dutour, Inès Abdesselam, Patricia Ancel, et al.
Diabetes Obesity and Metabolism (2016) Vol. 18, Iss. 9, pp. 882-891
Closed Access | Times Cited: 215
Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes. The Lira-NAFLD study
Jean‐Michel Petit, Jean–Pierre Cercueil, Romaric Loffroy, et al.
The Journal of Clinical Endocrinology & Metabolism (2016), pp. jc.2016-2775
Open Access | Times Cited: 209
Page 1 - Next Page

Scroll to top